Media Summary: (1 Mar 1964) Scenes from inside the court after the conviction of Jack Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses subgroup analyses from the US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the ...

Can 126 Ruby Trial - Detailed Analysis & Overview

(1 Mar 1964) Scenes from inside the court after the conviction of Jack Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses subgroup analyses from the US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the ... Mansoor Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the clinical In this MOASC Spotlight on Oncology session, Joshua Cohen, MD, City of Hope Orange County, reviews key advances in ... This is the biggest change in PE management since in 15 years - how should this affect your practice? Lots of high yield ...

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of 5-year results and correlative analysis of ... Precision Cancer Medicine specialist, Alex Rolland, discusses the truth about CDK4/6 inhibitors in the treatment of ER positive ... Dr Maurie Markman discusses results from the DUO-E A comprehensive commentary on Pokémon Omega In this MOASC Spotlight on Oncology session, Lee Cranmer, MD, City of Hope, reviews important advances in soft tissue sarcoma ...

Photo Gallery

CAN 126 RUBY TRIAL
Time to next treatment by age in the RUBY trial of dostarlimab in endometrial cancer
'Breakthrough' mRNA cancer drug curbs melanoma in large trial • FRANCE 24 English
LIVE: Lindsay Clancy trial Day 18
Clinical trials in gynecological research: Ruby, NORA and IMagyn050
What’s New in Gynecologic Cancer: Relacorilant & ROSELLA Trial | MOASC Spotlight
What Changed In The New 2026 Guidelines For Acute PE?
5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC
ESC 2026 Trials to Watch with Prof Van Mieghem & Dr Bertrand
The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers
DUO-E: PARP Inhibitor Combination Improves Survival in Endometrial Cancer
An Exhaustive Look at Pokémon Omega Ruby
View Detailed Profile
CAN 126 RUBY TRIAL

CAN 126 RUBY TRIAL

(1 Mar 1964) Scenes from inside the court after the conviction of Jack

Time to next treatment by age in the RUBY trial of dostarlimab in endometrial cancer

Time to next treatment by age in the RUBY trial of dostarlimab in endometrial cancer

Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses subgroup analyses from the

'Breakthrough' mRNA cancer drug curbs melanoma in large trial • FRANCE 24 English

'Breakthrough' mRNA cancer drug curbs melanoma in large trial • FRANCE 24 English

US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the ...

LIVE: Lindsay Clancy trial Day 18

LIVE: Lindsay Clancy trial Day 18

Live from court as the murder

Clinical trials in gynecological research: Ruby, NORA and IMagyn050

Clinical trials in gynecological research: Ruby, NORA and IMagyn050

Mansoor Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the clinical

What’s New in Gynecologic Cancer: Relacorilant & ROSELLA Trial | MOASC Spotlight

What’s New in Gynecologic Cancer: Relacorilant & ROSELLA Trial | MOASC Spotlight

In this MOASC Spotlight on Oncology session, Joshua Cohen, MD, City of Hope Orange County, reviews key advances in ...

What Changed In The New 2026 Guidelines For Acute PE?

What Changed In The New 2026 Guidelines For Acute PE?

This is the biggest change in PE management since in 15 years - how should this affect your practice? Lots of high yield ...

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of 5-year results and correlative analysis of ...

ESC 2026 Trials to Watch with Prof Van Mieghem & Dr Bertrand

ESC 2026 Trials to Watch with Prof Van Mieghem & Dr Bertrand

ESC 2026 Hot Line Preview: The

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

Precision Cancer Medicine specialist, Alex Rolland, discusses the truth about CDK4/6 inhibitors in the treatment of ER positive ...

DUO-E: PARP Inhibitor Combination Improves Survival in Endometrial Cancer

DUO-E: PARP Inhibitor Combination Improves Survival in Endometrial Cancer

Dr Maurie Markman discusses results from the DUO-E

An Exhaustive Look at Pokémon Omega Ruby

An Exhaustive Look at Pokémon Omega Ruby

A comprehensive commentary on Pokémon Omega

Soft Tissue Sarcoma 2026 Update: Trabectedin, Abemaciclib & Key Data | Lee Cranmer, MD

Soft Tissue Sarcoma 2026 Update: Trabectedin, Abemaciclib & Key Data | Lee Cranmer, MD

In this MOASC Spotlight on Oncology session, Lee Cranmer, MD, City of Hope, reviews important advances in soft tissue sarcoma ...